Skip to main content
. 2016 Jul 18;7(35):56558–56573. doi: 10.18632/oncotarget.10646

Figure 5. PXR mRNA expression correlates with ALDH1A1 expression and is a poor prognosis factor in colon cancer patients.

Figure 5

a. RT-qPCR analyses of PXR and ALDH1A1 mRNA expression, b. detection of PXR, ALDH1A1 and GAPDH protein expression by Western blotting after loss- (shPXR) or gain of PXR expression (PXR2). a: Data are expressed as mean ± SEM (n≥3) compared to LS174T control cells (shLUC) (F.I., Fold Induction). b: N.E.= nuclear extracts, C.E.= cytosolic extracts. c. Quantification of ALDH activity using the Aldefluor assay. Percentages of ALDHbr cells are indicated in inset boxes. d. Correlation between PXR and ALDH1A1 mRNA expression in CRC primary tumors of stage II or III patients treated with 5-FU-based chemotherapy (n=78) or in human liver metastasis samples (n=12) obtained from patients with metastatic colorectal disease. e. Kaplan-Meier estimates of the probability of resting free from tumor recurrence, according to PXR expression level in CRC primary tumors of stage II & III (upper panel), or stage II (lower panel) patients treated with 5-FU-based chemotherapy. PXR expression was normalized according to RPLO mRNA expression. Patients with low PXR gene expression are depicted in blue and patients with high PXR gene expression in red. p value from the likelihood ratio test is shown in each case.